Předmět
Publikace
- External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score2021 | 3. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group2021 | Ústřední knihovna, Lékařská fakulta v Hradci Králové
- Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group2020 | 1. lékařská fakulta, 3. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Frontline treatment with the combination obinutuzumab +/- chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group2020 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus2020 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Richterova transformace chronické lymfocytární leukemie v éře léčby inhibitory buněčných drah2020 | 1. lékařská fakulta
- Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study2020 | 1. lékařská fakulta
- Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study2020 | 1. lékařská fakulta
- Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab2019 | 1. lékařská fakulta, 3. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Single-agent ibrutinib in RESONATE-2TM and RESONATETM versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia2019 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
Loading network view...